Shares in AstraZeneca bounced this week after the US government signalled that it is considering fast-track approval for the group’s Covid-19 vaccine. In April AstraZeneca agreed a deal with Oxford University, which originally discovered the vaccine, to develop and distribute it.
The government could ask the US Food and Drug Administration (FDA) to grant an “emergency use authorisation” (EUA) based on data from the final-stage UK trial, rather than wait for the more extended study normally required by US regulators. Such a move, possible as early as September, would allow President Donald Trump to claim he has “turned the tide” on the virus. Not so fast, say Rhys Blakely and Henry Zeffman in The Times. AstraZeneca says it is “too early” to begin talks with US regulators about an EUA. Nonetheless, 17,000 people have been enrolled in trials in Britain, South Africa and Brazil. So if enough data emerged to convince AstraZeneca to apply for an EUA, the FDA would be under pressure to grant it quickly. It has already approved 21 Covid-19 drugs, including an antibody treatment, on an emergency basis.
Meanwhile, says Bloomberg, Pfizer and BioNTech claim that their joint Covid-19 vaccine is “on track” to be submitted for regulatory review “as early as October”. The companies, which recently clinched a $2bn deal to supply 100 million doses to the US government, released more detailed data from early-stage trials suggesting that the drug was “well tolerated” with “mild to moderate fever in fewer than 20% of participants”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
UK mid-caps: an improving outlookUK mid-caps have perked up and the rally may run further, but long-term investors should remain selective
-
The tobacco industry is going smoke-free - how to profit from itTobacco companies have realised their traditional products are on the wane. But new opportunities have opened up – and should prove lucrative
-
Is it time to invest in creative industries?Any industrial strategy should not overlook the creative industries, one of our top national assets
-
Is Mercia Asset Management set for success?Mercia Asset Management helps the government fund smaller companies in Britain’s regions. Should you invest?
-
British stocks set for a boostBritish stocks are due for a bounce as the UK looks more stable compared to many economies
-
Ocado shares jump by a fifthOcado takes a turn for the better after attractive profit forecasts were announced
-
The AI boom is on borrowed timeThe hype around the AI boom could be on its way out – but why?
-
Diploma: a blue-chip set for strong growthDiploma, whose niche products include seals and fasteners, serves an array of growth markets. Should you invest?
